C Cursiefen1, L M Heindl. 1. Augenklinik des Universitätsklinikums Köln, Universität zu Köln, Joseph-Stelzmann Str. 9, 50924, Köln, Deutschland. claus.cursiefen@uk-koeln.de
Abstract
PURPOSE: The current indications, techniques, results and complications of deep anterior lamellar keratoplasty are described. METHODS: The study comprised a literature review and own clinical and experimental results. RESULTS: The main advantage of DALK in patients with keratoconus and other anterior stromal diseases is the avoidance of endothelial immune reactions and the main drawback is the conversion rate to penetrating keratoplasty of around 15%. CONCLUSIONS: Using the big bubble approach DALK is a safe and reliable technique for treating keratoconus and anterior stromal dystrophy.
PURPOSE: The current indications, techniques, results and complications of deep anterior lamellar keratoplasty are described. METHODS: The study comprised a literature review and own clinical and experimental results. RESULTS: The main advantage of DALK in patients with keratoconus and other anterior stromal diseases is the avoidance of endothelial immune reactions and the main drawback is the conversion rate to penetrating keratoplasty of around 15%. CONCLUSIONS: Using the big bubble approach DALK is a safe and reliable technique for treating keratoconus and anterior stromal dystrophy.
Authors: Daniel Böhringer; Stefan Böhringer; Katharina Poxleitner; Florian Birnbaum; Johannes Schwartzkopff; Philip Maier; Rainer Sundmacher; Thomas Reinhard Journal: Cornea Date: 2010-10 Impact factor: 2.651
Authors: William J Reinhart; David C Musch; Deborah S Jacobs; W Barry Lee; Stephen C Kaufman; Roni M Shtein Journal: Ophthalmology Date: 2011-01 Impact factor: 12.079
Authors: Yanny Y Y Cheng; Nienke Visser; Jan S Schouten; Robert-Jan Wijdh; Elisabeth Pels; Hugo van Cleynenbreugel; Catharina A Eggink; Michel J W Zaal; Wilhelmina J Rijneveld; Rudy M M A Nuijts Journal: Ophthalmology Date: 2010-09-15 Impact factor: 12.079
Authors: Friederike Schaub; Philip Enders; Björn O Bachmann; Ludwig M Heindl; Claus Cursiefen Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-01-30 Impact factor: 3.117